A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in aHUS Patients in South Korea

A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in Atypical Hemolytic Uremic Syndrome (aHUS) Patients in South Korea

Primary objective

- To determine the clinical prognosis by identifying the disease course and severity by treatment with or without eculizumab in patients with aHUS in Korea.

Secondary objectives

• To determine the clinical prognosis of the disease in all patients with aHUS in Korea.
• To determine the clinical prognosis of the disease in patients diagnosed with aHUS prior to the initiation of eculizumab reimbursement system in Korea.
• To determine the treatment responses by treatment options in patients with aHUS in Korea.
• To identify risk factors that affect mortality in all patients with aHUS in Korea.
• To investigate the recurrence and clinical prognosis in patients with aHUS in Korea when eculizumab is discontinued

As a retrospective, non-interventional, multi-center study

Inclusion Criteria:

• Patients who are clinically diagnosed with the aHUS

Exclusion Criteria:

• Patients who are diagnosed with Shiga toxin-producing E. coli hemolytic-uremic syndrome (STEC-HUS).
• Patients with less than 10% in a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS-13) activity test